common
cold
preval
contagi
viral
diseas
human
caus
varieti
viral
pathogen
human
rhinovirus
hrv
abund
one
affect
upper
respiratori
system
symptom
like
block
nose
cough
sneez
common
socioeconom
loss
associ
viral
respiratori
tract
infect
howev
huge
enorm
direct
indirect
cost
health
care
system
cold
also
pose
threat
young
old
ail
andor
high
risk
group
like
immunocompromis
patient
copd
patient
asthmat
lung
transplant
recipi
wide
rang
remedi
sold
prescript
counter
evidencebas
medicin
systemat
review
conclud
still
reliabl
prevent
cure
avail
potenti
seriou
side
effect
popular
product
also
consid
given
multipl
caus
common
cold
cochran
collabor
suggest
focu
futur
research
effort
non
virusspecif
compound
effect
formul
contain
antivir
agent
need
safe
efficaci
treatment
common
cold
symptom
contain
viral
propag
potenti
side
effect
also
minim
due
usual
nonhazard
natur
indic
carrageenan
sulphat
galactos
polym
deriv
rhodophycea
seawe
commonli
use
food
prepar
topic
product
gell
emulsifi
properti
three
main
copolym
design
iota
kappa
lambda
depend
number
locat
sulphat
moieti
hexos
scaffold
structur
carrageenan
compound
us
food
drug
administr
gener
recogn
safe
gra
list
product
consumpt
topic
applic
pharmaceut
industri
carrageenan
use
topic
formul
daili
dose
level
mgperson
recent
public
present
invitro
find
antivir
properti
iotacarrageenan
hrv
add
proof
previou
find
antivir
properti
virus
present
exploratori
studi
design
determin
magnitud
effect
iotacarrageenan
nasal
spray
sever
common
cold
symptom
rel
placebo
treatment
secondari
object
analys
effect
biomark
level
presenc
common
cold
virus
nasal
lavag
sampl
healthi
volunt
year
brief
advanc
sign
consent
declar
prior
studyrel
procedur
recruit
studi
anonym
guarante
studi
data
inform
subject
kept
safe
prevent
commun
third
parti
subject
free
withdraw
studi
time
without
prejudic
treatment
follow
symptom
assess
inclus
studi
studi
day
local
symptom
sore
throat
block
nose
runni
nose
cough
sneez
system
symptom
defin
headach
muscl
ach
chilli
symptom
assess
point
scale
none
symptom
present
previou
h
mild
sensibl
disturb
irrit
moder
symptom
sometim
disturbingirrit
sever
symptom
disturbingirrit
time
score
system
develop
jackson
wide
use
common
cold
clinic
trial
order
recruit
subject
earli
onset
common
cold
studi
entri
subject
symptom
score
greater
sore
throat
runni
block
nose
total
symptom
score
less
sum
sever
score
compris
headach
muscl
ach
chilli
sore
throat
runni
nose
block
nose
cough
sneez
studi
particip
agre
refrain
take
medic
intend
prevent
interven
treat
coughscoldsflulik
symptom
start
studi
entri
continu
day
entrant
exclud
studi
follow
predefin
reason
unwil
sign
consent
form
known
hypersensit
allergi
compon
studi
medic
clinic
signific
cardiovascular
endocrin
neurolog
respiratori
gastrointestin
diseas
histori
current
diseas
consid
investig
exclus
criteria
eg
current
allerg
rhiniti
chronic
obstruct
pulmonari
diseas
copd
although
explicitli
mention
studi
protocol
asthma
exclus
criterion
patient
asthma
recruit
furthermor
subject
also
exclud
investig
sever
nasal
septum
deviat
condit
present
could
caus
nasal
obstruct
nasal
polyp
nasalsinu
surgeri
past
influenc
symptom
score
addit
particip
histori
alcoholsubst
abus
prescript
medicationconcomit
therapi
contracept
eg
system
steroid
intranas
medicin
antibiot
also
exclud
investig
reason
exclus
incid
common
cold
flu
like
symptom
h
current
smoke
relationship
studi
personnel
administr
investig
drug
particip
clinic
trial
within
week
entri
studi
coexist
diseas
condit
treat
accord
prevail
medic
practic
current
studi
design
singl
centr
randomis
doubleblind
parallel
group
placebocontrol
compar
survey
subject
earli
symptom
common
cold
assess
efficaci
iotacarrageenan
nasal
spray
earli
treatment
natur
cold
chosen
research
design
control
group
variabl
assess
standard
field
research
ordin
scale
use
studi
flow
chart
shown
figur
subject
random
done
follow
verif
inclusionexclus
criteria
neither
investig
subject
knew
assign
treatment
random
perform
provid
test
nasal
spray
uniqu
code
number
random
subject
assign
nasal
spray
visit
treatment
day
subject
complet
daili
diari
common
cold
symptom
score
day
underw
nasal
lavag
day
first
treatment
day
nasal
dose
studi
medic
day
studi
conduct
februari
may
common
cold
nasal
research
centr
cardiff
school
bioscienc
cardiff
univers
uk
symptom
applic
treatment
document
patient
diari
code
perform
cro
bioconsult
gmbh
perchtoldsdorf
austria
decod
trial
review
data
base
lock
studi
perform
complianc
ich
note
guidanc
good
clinic
practic
principl
declar
helsinki
local
drug
law
standard
oper
procedur
investig
sponsor
cro
involv
studi
protocol
attach
document
consent
form
subject
inform
crf
etc
approv
respons
south
east
wale
local
research
ethic
committe
sign
studi
protocol
avail
journal
editor
review
process
trial
regist
european
clinic
trial
registri
eudract
number
primari
efficaci
measur
defin
prospect
mean
total
symptom
score
tss
studi
day
tss
sum
individu
symptom
score
describ
maximum
tss
score
record
time
point
statist
analysi
tss
studi
day
summar
per
subject
individu
mean
calcul
secondari
efficaci
measur
defin
prospect
tss
separ
studi
day
mean
total
system
symptom
score
tsss
headach
muscl
ach
chilli
studi
day
tsss
separ
studi
day
secondari
efficaci
variabl
local
symptom
score
lss
sore
throat
block
nose
runni
nose
cough
sneez
mean
studi
day
separ
studi
day
individu
symptom
score
iss
headach
muscl
ach
chilli
sore
throat
block
nose
runni
nose
cough
sneez
separ
studi
day
exploratori
efficaci
variabl
includ
viru
detectiontot
viral
load
cytokin
express
detect
nasal
lavag
subject
accept
test
nasal
spray
use
visual
analogu
scale
va
furthermor
data
subject
willing
use
product
futur
via
ordin
scale
strongli
agre
agre
disagre
strongli
disagre
collect
iotacarrageenan
nasal
spray
verum
unlabel
coldamari
gl
nacl
gl
water
inject
wfi
ad
ml
g
placebo
nacl
gl
wfi
ad
ml
g
manufactur
mono
chempharm
produkt
gmbh
vienna
austria
spray
solut
clear
colourless
odourless
free
particl
verum
placebo
nasal
spray
ident
shape
size
colour
allow
doubleblind
design
random
cro
administr
spray
shaken
prime
fine
mist
deliv
one
spray
applic
deliv
nostril
day
day
first
applic
taken
studi
entri
pm
next
two
applic
spray
equal
space
remain
wake
hour
day
nasal
spray
applic
day
administ
equal
space
wake
hour
control
complianc
studi
protocol
return
spray
bottl
weight
weight
compar
weight
dispens
therebi
evalu
weight
medic
taken
studi
period
subject
placebo
miss
first
dose
day
third
dose
day
therefor
took
plan
dose
subject
complianc
accord
diari
document
total
complianc
reach
studi
depend
time
point
inclus
studi
expect
rang
differ
weight
g
g
mean
differ
verum
group
g
g
placebo
group
g
g
conclud
placebo
verum
dose
administ
result
support
good
complianc
report
subject
diari
onset
common
cold
symptom
day
visit
display
addit
file
tabl
nasal
lavag
perform
day
studi
inclus
day
sampl
collect
instil
ml
steril
salin
nostril
wash
expel
wax
paper
cup
sampl
pool
per
subject
process
within
h
part
lavag
mix
part
bovin
albumin
sigma
aldrich
vienna
austria
part
proteas
inhibitor
cocktail
roch
germani
portion
sampl
store
analysi
determin
respiratori
viru
load
viru
identif
nasal
lavag
real
time
pcr
analysi
perform
influenza
viru
type
b
respiratori
syncyti
viru
type
b
parainfluenza
viru
type
coronaviru
type
rhinovirus
majorminor
group
virus
human
metapneumoviru
assay
perform
use
qiaamp
viral
rna
mini
qiagen
quantifast
probe
pcr
kit
qiagen
gmbh
hilden
germani
realaccur
respiratori
rt
pcr
kit
pathofind
maastricht
netherland
real
time
pcr
ht
sequenc
detect
appli
biosystem
foster
citi
usa
accord
manufactur
instruct
setup
enabl
detect
rna
virus
account
approxim
respiratori
tract
infect
brief
sampl
thaw
ice
transfer
buffer
avl
carrier
rna
spike
intern
control
eluat
rna
store
maximum
hour
transfer
rtpcr
reaction
perform
final
volum
follow
realtim
cycler
condit
use
min
revers
transcript
min
activ
taq
dna
polymeras
inactiv
revers
transcriptas
denatur
anneal
extens
cycl
ct
valu
posit
sampl
antilog
basi
result
valu
viru
posit
sampl
first
visit
set
rel
quantiti
viru
posit
sampl
second
visit
calcul
percent
valu
first
visit
lavag
sampl
assay
duplic
measur
rel
cytokin
quantiti
cytokin
concentr
determin
milliplex
map
human
cytokinechemokin
kit
well
plate
assay
millipor
corp
st
charl
usa
accord
manufactur
instruct
nacl
use
matrix
compli
lavag
medium
follow
cytokin
measur
egf
eotaxin
fractalkin
gcsf
gmcsf
gro
includ
gro
alpha
beta
gamma
mdc
vegf
fluoresc
determin
luminex
reader
data
analys
luminex
softwar
riversid
ca
usa
use
paramet
logist
curv
fit
method
lower
quantif
limit
pgml
valu
set
zero
duplic
result
detect
concentr
omit
analysi
comparison
group
done
mean
mannwhitney
utest
continu
variabl
mean
chi
squar
test
ordin
nomin
distribut
variabl
test
treatment
group
perform
mannwhitney
utest
test
within
group
wilcoxon
match
pair
sign
rank
test
use
trial
design
exploratori
studi
magnitud
effect
nasal
spray
common
cold
symptom
unknown
base
experi
studi
centr
calcul
studi
number
healthi
subject
provid
suffici
data
determin
effect
nasal
symptom
allow
power
calcul
studi
subject
screen
enrol
random
one
subject
iotacarrageenan
lost
follow
initi
screen
visit
addit
data
obtain
subject
complet
studi
drug
administr
includ
safeti
analysi
demograph
data
studi
flow
chart
shown
figur
two
subject
exclud
analysi
symptom
due
protocol
violat
defin
exclus
criterion
studi
protocol
subject
report
vomit
nausea
abdomin
pain
presum
caus
infect
gastrointestin
tract
furthermor
use
ibuprofen
concomit
medic
subject
report
migrain
treat
ibuprofen
swollen
eye
due
presum
allerg
reaction
treat
oral
antihistamin
observ
period
subject
therefor
exclud
efficaci
analysi
symptom
total
iotacarrageenan
patient
placebo
patient
elig
analysi
symptom
predefin
primari
efficaci
paramet
trial
differ
iotacarrageenan
placebo
total
symptom
score
day
tss
iotacarrageenan
nasal
spray
superior
placebo
p
respect
primari
endpoint
mean
tss
day
tabl
mean
total
symptom
score
day
shown
figur
efficaci
iotacarrageenan
nasal
spray
treatment
appear
mainli
observ
local
symptom
score
lss
sore
throat
block
nose
runni
nose
cough
sneez
littl
differ
treatment
system
symptom
score
sss
headach
muscl
ach
chilli
figur
reflect
result
lss
sss
mean
sum
day
lower
iotacarrageenan
patient
signific
level
respect
tabl
statist
differ
tss
day
p
differ
signific
day
p
indic
faster
relief
symptom
iotacarrageenan
group
averag
individu
symptom
score
block
nose
runni
nose
cough
sneez
higher
placebo
compar
verum
figur
individu
symptom
block
nose
runni
nose
show
highest
score
indic
symptom
bothersom
individu
lss
trend
toward
superior
iotacarrageenan
nasal
spray
observ
inclus
subject
report
slightli
higher
score
iotacarrageenan
group
symptom
block
nose
cough
sore
throat
three
symptom
show
increas
placebo
group
iotacarrageenan
group
next
report
time
point
result
suggest
iotacarrageenan
nasal
spray
treatment
inhibitori
effect
develop
common
cold
symptom
shortli
start
therapi
studi
end
point
day
placebo
patient
report
mean
block
nose
score
contrast
iotacarrageenan
patient
report
mean
block
nose
score
correspond
reduct
approxim
figur
post
hoc
analysi
symptom
reveal
iotacarrageenan
patient
report
symptom
block
nose
end
studi
placebo
group
subject
free
symptom
nasal
lavag
analyz
quantit
real
time
rtpcr
presenc
viral
genom
sampl
iotacarrageenan
placebo
patient
viru
posit
patient
test
posit
human
rhinoviru
anoth
patient
coronaviru
one
patient
parainfluenza
viru
shown
figur
viral
load
placebo
group
increas
almost
fold
dramat
decreas
iotacarrageenan
group
p
result
indic
treatment
patient
iota
carrageenan
nasal
spray
lead
highli
statist
signific
reduct
viral
load
nasal
caviti
placebo
treatment
influenc
viral
replic
basi
statist
analysi
ctvalu
shown
addit
file
tabl
nasal
lavag
patient
exclud
due
protocol
violat
test
neg
respiratori
virus
data
shown
analysi
cytokin
reveal
median
level
follow
cytokin
detect
limit
pgml
egf
eotaxin
gmcsf
mdc
vegf
rel
low
level
paramet
suggest
major
biolog
relev
time
point
sampl
consequ
analysi
cytokin
carri
cytokin
found
present
highest
concentr
test
cytokin
decreas
pgml
first
visit
averag
pgml
day
iotacarrageenan
group
increas
pgml
placebo
group
day
day
tabl
howev
due
high
standard
deviat
differ
level
iotacarrageenan
placebo
signific
much
lower
level
similar
effect
observ
gro
gcsf
differ
even
signific
p
fractalkin
p
contrast
two
molecul
known
function
antagonist
inflamm
higher
iotacarrageenan
group
howev
result
allow
hypothes
observ
reduct
viral
replic
result
lower
level
proinflammatori
cytokin
consequ
lower
symptom
score
product
accept
subject
iotacarrageenan
placebo
nasal
spray
respect
significantli
higher
iotacarrageenan
itt
p
pp
p
also
viru
posit
patient
p
tabl
pp
subject
use
iotacarrageenan
subject
use
placebo
oppos
futur
consist
medic
note
placebo
formul
ident
verum
except
iotacarrageenan
show
compon
iotacarrageenan
nasal
spray
except
well
toler
subject
remark
even
increas
support
virusposit
subject
result
indic
observ
benefit
iotacarrageenantr
patient
level
symptom
score
biomark
correl
higher
product
accept
seriou
advers
event
sae
report
withdraw
due
advers
event
ae
develop
ae
list
patient
includ
report
term
investig
meddra
prefer
term
pt
meddra
system
organ
class
soc
subject
iotacarrageenan
placebo
experienc
least
one
ae
iotacarrageenan
patient
report
three
ae
vomit
nausea
abdomin
pain
use
ibuprofen
concomit
medic
therefor
exclud
efficaci
analysi
symptom
ae
consid
associ
studi
medic
iotacarrageenan
patient
report
migrain
puffi
eye
lid
use
ibuprofen
antihistamin
concomit
medic
therefor
exclud
efficaci
analysi
symptom
one
iotacarrageenan
patient
report
loss
voic
anoth
iotacarrageenan
patient
report
dri
mouth
intermitt
epistaxi
report
placebo
patient
total
ae
report
rate
possibl
relat
treatment
dri
mouth
iotacarrageenan
n
itt
pp
group
puffi
eye
lid
iotacarrageenan
n
addit
file
tabl
sinc
side
effect
resolv
special
action
necessari
small
number
ae
report
support
particular
good
safetyprofil
iotacarrageenan
activ
agent
iotacarrageenan
nasal
spray
compon
gener
result
studi
indic
iota
carrageenan
nasal
spray
safe
effect
treatment
taken
within
hour
develop
common
cold
symptom
design
exploratori
trial
size
studi
rel
small
reach
statist
signific
p
predefin
primari
endpoint
tss
mean
sum
day
patient
report
rel
low
level
system
symptom
indic
sever
infect
respiratori
tract
occur
figur
efficaci
iotacarrageenan
nasal
spray
treatment
appear
mainli
depend
local
symptom
score
lss
sore
throat
block
nose
runni
nose
cough
sneez
tabl
figur
interestingli
placebo
iotacarrageenan
patient
report
symptom
block
nose
end
studi
period
although
explicitli
test
conclud
fact
one
main
reason
significantli
better
accept
patient
iotacarrageenan
nasal
spray
tabl
iotacarrageenan
placebo
group
reach
mean
tss
level
around
end
day
observ
period
figur
studi
medic
appli
first
day
could
reason
complet
relief
symptom
occur
studi
period
day
conclud
longer
treatment
observ
period
consid
futur
trial
better
determin
therapeut
effect
iotacarrageenan
nasal
spray
studi
popul
consist
mainli
student
mean
age
sd
year
complianc
high
sinc
age
group
reflect
small
proport
gener
popul
studi
might
serv
best
case
indic
design
bigger
trial
target
popul
gener
well
known
studi
antivir
substanc
earli
intervent
correl
efficaci
vast
major
patient
report
symptom
day
less
day
inclus
studi
addit
file
tabl
conclud
treatment
common
cold
iotacarrageenan
nasal
spray
effect
start
earli
onset
symptom
iotacarrageenan
nasal
spray
formul
solut
iotacarrageenan
nacl
water
intend
direct
intranas
applic
test
effect
blind
studi
medic
carri
although
studi
medic
group
appear
complet
ident
might
weak
studi
independ
review
randomis
control
clinic
trial
upper
respiratori
tract
infect
show
limit
evid
benefit
salin
nasal
irrig
howev
use
treatment
wide
accept
trial
obtain
satisfactori
result
nasal
caviti
site
choic
inhibit
common
cold
viru
infect
replic
iotacarrageenan
effect
complement
known
efficaci
safeti
patient
satisfact
salin
nasal
irrig
acut
chronic
rhino
sinus
via
naclwfi
spray
compon
serv
placebo
studi
symptomat
benefit
iotacarrageenan
patient
correl
well
decreas
detect
viru
genom
copi
nasal
lavag
patient
figur
statist
analysi
viru
posit
patient
reveal
pvalu
differ
iotacarrageenan
nasal
spray
placebo
sinc
number
viru
positivetest
subject
low
confirm
result
need
rule
patient
infect
respiratori
virus
test
detect
limit
howev
result
patient
support
earlier
invitro
find
antivir
effect
human
rhinovirus
virus
papillomavirus
dengu
viru
result
studi
might
encourag
clinic
develop
virus
well
common
cold
symptom
caus
reaction
immun
system
virus
viru
infect
cell
well
local
newli
recruit
immun
cell
nasal
lavag
sampl
presenc
immun
mediat
test
major
growth
factor
cytokin
express
detect
limit
mediat
includ
gro
easili
detect
interest
note
express
major
molecul
fractalkin
gro
gcsf
reduc
iotacarrageenan
group
upon
treatment
receptor
antagonist
increas
receptor
antagonist
regard
counteract
molecul
role
respiratori
infect
human
fulli
understood
recent
studi
suggest
suggest
endogen
essenti
inhibit
airway
hyperrespons
peribronchi
fibrosi
eosinophil
inflamm
murin
asthma
model
prolong
antigen
exposur
result
suggest
treatment
iotacarrageenan
reduc
viral
replic
consequ
fewer
cell
infect
immun
reaction
virus
less
pronounc
fewer
symptom
occur
addit
report
express
proinflammatori
mediat
cours
common
cold
may
worsen
preexist
comorbid
asthma
copd
therefor
reduct
immun
respons
due
lower
viral
load
appear
attract
properti
novel
treatment
iota
carrageenan
nasal
spray
use
studi
may
reduc
sever
nasal
symptom
antivir
effect
rather
pharmacolog
effect
nasal
blood
vessel
gland
advantag
pharmacolog
intervent
control
symptom
nasal
decongest
antisecretori
agent
associ
side
effect
nasal
bleed
crust
young
children
respiratori
symptom
major
spreader
rhinoviru
famili
set
rhinoviru
infect
common
caus
hospit
children
often
wheez
vast
bulk
viral
transmiss
occur
among
children
famili
intervent
affect
transmiss
would
great
socioeconom
valu
lack
toxic
pharmacolog
activ
iota
carrageenan
nasal
spray
high
safeti
profil
mean
treatment
may
suitabl
use
children
well
adult
iotacarrageenan
nasal
spray
appear
promis
compound
safe
effect
treatment
earli
symptom
common
cold
larger
clinic
trial
need
studi
therapeut
index
detail
trial
fund
marinom
biotechnologi
gmbh
rec
mja
receiv
direct
payment
marinom
author
epg
agr
cme
rwe
employ
marinom
author
agr
epg
cofound
marinom
agr
epg
coinventor
patent
held
marinom
biotechnologi
gmbh
relat
content
manuscript
marinom
biotechnologi
gmbh
financ
process
charg
manuscript
rec
princip
investig
studi
respons
studi
protocol
design
mja
perform
studi
site
serv
medic
director
rwe
cme
perform
quantit
viru
analysi
cytokin
analysi
agr
epg
mja
rec
particip
design
statist
analys
coordin
studi
interpret
data
write
manuscript
author
read
approv
final
manuscript
